Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allon Therapeutics (Allon) has presented preclinical data demonstrating the efficacy of AL-309, the company's early-stage drug candidate. AL-309 is being investigated as a treatment for peripheral neuropathy.
Subscribe to our email newsletter
Bruce Morimoto, vice president of drug development at Allon, said the preclinical data has shown AL-309 to be effective in reducing nerve damage and pain in animal models for peripheral neuropathy caused by diabetes and cancer chemotherapy, two of the most common causes of the disease.
He presented the data at the AsiaTIDES Oligonucleotide and Peptide Technology and Product Development Conference in Tokyo, Japan. AsiaTIDES focuses on technology and product development, manufacturing and partnering in the fields of oligonucleotide and peptide-based therapeutics and diagnostics.
Dr Morimoto said: “The preclinical data has shown AL-309 to be effective at reducing nerve damage and pain in animal models for peripheral neuropathy caused by diabetes and cancer chemotherapy, two of the most common causes of the disease.
“Our preclinical studies have shown that AL-309 not only reduced the pain symptoms associated with neuropathy, but also decreased nerve damage. Furthermore, the characteristics of AL-309 allow it to be developed for multiple routes of administration based on bioavailability studies using oral, intranasal, or subcutaneous application.”